Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

Abstract Background Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of these irAEs have not been illustrated clearly. In this study, we analyzed irAEs for seven FDA-approved ICIs in...

Full description

Bibliographic Details
Main Authors: Fan Yang, Chloe Shay, Marin Abousaud, Chris Tang, Yamin Li, Zhaohui Qin, Nabil F. Saba, Yong Teng
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
immune checkpoint inhibitors
Immunotherapy
Adverse events
Toxicity burden
Therapeutic intervention
Online Access:https://doi.org/10.1186/s13046-022-02568-y

Internet

https://doi.org/10.1186/s13046-022-02568-y

Similar Items